Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts

Inflammatory Bowel Diseases

Volumn 17, Issue 1, 2011, Pages 471-478

  Peyrin Biroulet, Laurent ^a   Loftus Jr , Edward V ^a   Colombel, Jean Frederic ^b   Sandborn, William J ^a  

^a MAYO CLINIC   (United States)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

colorectal cancer; colorectal dysplasia; Crohn's disease; demyelinating disorders; extraintestinal complications; mortality; natural history; osteoporosis; population based; small intestinal cancer; thromboembolism

Indexed keywords

ANKYLOSING SPONDYLITIS; ARTERY THROMBOSIS; ASTHMA; BONE DENSITY; BRONCHITIS; CANCER RISK; CEREBROVASCULAR DISEASE; COLORECTAL CANCER; CROHN DISEASE; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; ENTERITIS; ERYTHEMA NODOSUM; FOLLOW UP; FRACTURE; HIP FRACTURE; HUMAN; IRITIS; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; LYMPHOMA; MEDLINE; MORTALITY; MULTIPLE SCLEROSIS; OSTEOPENIA; OSTEOPOROSIS; PERICARDITIS; POPULATION BASED CASE CONTROL STUDY; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PSORIASIS; PYODERMA GANGRENOSUM; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SMALL INTESTINE CANCER; UVEITIS;

ADULT; CHOLELITHIASIS; COHORT STUDIES; CROHN DISEASE; ERYTHEMA NODOSUM; HUMANS; PYODERMA GANGRENOSUM; SPONDYLITIS, ANKYLOSING; TIME FACTORS;

EID: 78650083732     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21417     Document Type: Review

References (73)

1. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010; 105: 289-297.
2. Bernstein CN, Blanchard JF, Leslie W, et al. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med. 2000; 133: 795-799.
3. Loftus EV Jr, Crowson CS, Sandborn WJ, et al. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology. 2002; 123: 468-475.
4. Card T, West J, Hubbard R, et al. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut. 2004; 53: 251-255.
5. Bernstein CN,. Inflammatory bowel diseases as secondary causes of osteoporosis. Curr Osteoporos Rep. 2006; 4: 116-123.
6. Bernstein CN, Leslie WD, Taback SP,. Bone density in a population-based cohort of premenopausal adult women with early onset inflammatory bowel disease. Am J Gastroenterol. 2003; 98: 1094-1100.
7. Leslie WD, Miller N, Rogala L, et al. Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Am J Gastroenterol. 2008; 103: 1451-1459.
8. Leslie WD, Miller N, Rogala L, et al. Body mass and composition affect bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Inflamm Bowel Dis. 2009; 15: 39-46.
9. Schoon EJ, van Nunen AB, Wouters RS, et al. Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort. Scand J Gastroenterol Suppl. 2000; 43-47.
10. Schoon EJ, Blok BM, Geerling BJ, et al. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology. 2000; 119: 1203-1208.
11. Bernstein CN, Blanchard JF, Metge C, et al. The association between corticosteroid use and development of fractures among IBD patients in a population-based database. Am J Gastroenterol. 2003; 98: 1797-1801.
12. Tang BM, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet. 2007; 370: 657-666.
13. Bernstein CN, Wajda A, Blanchard JF,. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol. 2008; 6: 41-45.
14. Bernstein CN, Blanchard JF, Houston DS, et al. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost. 2001; 85: 430-434.
15. Bernstein CN, Sargent M, Vos HL, et al. Mutations in clotting factors and inflammatory bowel disease. Am J Gastroenterol. 2007; 102: 338-343.
16. Kimura K, Hunter SF, Thollander MS, et al. Concurrence of inflammatory bowel disease and multiple sclerosis. Mayo Clin Proc. 2000; 75: 802-806.
17. Gupta G, Gelfand JM, Lewis JD,. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology. 2005; 129: 819-826.
18. Bernstein CN, Blanchard JF, Rawsthorne P, et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001; 96: 1116-1122.
19. Bernstein CN, Wajda A, Blanchard JF,. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology. 2005; 129: 827-836.
20. Weng X, Liu L, Barcellos LF, et al. Clustering of inflammatory bowel disease with immune mediated diseases among members of a northern California-managed care organization. Am J Gastroenterol. 2007; 102: 1429-1435.
21. Fenta Y, Tello N JJ, Li B, et al. Asthma and inflammatory bowel disease: a population-based retrospective case-control study. Am J Respir Crit Care Med. 2009; 179: A2181.
22. Figueroa JJ, Dyck PJB, Loftus EV, et al. Neuropathy in population with inflammatory bowel disease in Olmsted County, Minnesota. J Periph Nerv Syst. 2009; 14 (Suppl): A48.
23. Ordonez NT, Fenta Y, Loftus E, et al. Atopy and inflammatory bowel disease: a population-based retrospective case-control study. Allergy. 2009; 64: A493-494.
24. Palm O, Moum B, Ongre A, et al. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol. 2002; 29: 511-515.
25. West J, Logan RF, Hubbard RB, et al. Risk of schizophrenia in people with coeliac disease, ulcerative colitis and Crohn's disease: a general population-based study. Aliment Pharmacol Ther. 2006; 23: 71-74.
26. Van Staa TP, Travis S, Leufkens HG, et al. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology. 2004; 126: 1733-1739.
27. Gupta G, Lautenbach E, Lewis JD,. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006; 4: 1483-1490.
28. Jess T, Loftus EV Jr, Velayos FS, et al. Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Inflamm Bowel Dis. 2006; 12: 669-676.
29. Katsanos KH, Vermeire S, Christodoulou DK, et al. Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative follow-up study. Digestion. 2007; 75: 113-121.
30. Jess T, Gamborg M, Matzen P, et al. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol. 2005; 100: 2724-2729.
31. Canavan C, Abrams KR, Mayberry J,. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther. 2006; 23: 1097-1104.
32. von Roon AC, Reese G, Teare J, et al. The risk of cancer in patients with Crohn's disease. Dis Colon Rectum. 2007; 50: 839-855.
33. Jess T, Loftus EV Jr, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology. 2006; 130: 1039-1046.
34. Ekbom A, Helmick C, Zack M, et al. Extracolonic malignancies in inflammatory bowel disease. Cancer. 1991; 67: 2015-2019.
35. Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001; 91: 854-862.
36. Fireman Z, Grossman A, Lilos P, et al. Intestinal cancer in patients with Crohn's disease. A population study in central Israel. Scand J Gastroenterol. 1989; 24: 346-350. (Pubitemid 19110894)
37. Persson PG, Karlen P, Bernell O, et al. Crohn's disease and cancer: a population-based cohort study. Gastroenterology. 1994; 107: 1675-1679.
38. Jess T, Winther KV, Munkholm P, et al. Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther. 2004; 19: 287-293.
39. Hemminki K, Li X, Sundquist J, et al. Cancer risks in Crohn disease patients. Ann Oncol. 2009; 20: 574-580.
40. Soderlund S, Brandt L, Lapidus A, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology. 2009; 136: 1561-1567.
41. Jones JL, Loftus EV Jr,. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis. 2007; 13: 1299-1307.
42. Loftus EV Jr, Tremaine WJ, Habermann TM, et al. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2000; 95: 2308-2312.
43. Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001; 121: 1080-1087.
44. Palli D, Trallori G, Bagnoli S, et al. Hodgkin's disease risk is increased in patients with ulcerative colitis. Gastroenterology. 2000; 119: 647-653.
45. Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut. 2005; 54: 617-622.
46. Sokol H, Beaugerie L,. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut. 2009; 58: 1427-1436.
47. Pedersen N, Duricova D, Elkjaer M, et al. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol. 2010 [Epub ahead of print].
48. Singh H, Demers AA, Nugent Z, et al. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based, nested, case-control study. Gastroenterology. 2009; 136: 451-458.
49. Kane S, Khatibi B, Reddy D,. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008; 103: 631-636.
50. Hutfless S, Fireman B, Kane S, et al. Screening differences and risk of cervical cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2008; 28: 598-605.
51. Prior P, Gyde S, Cooke WT, et al. Mortality in Crohn's disease. Gastroenterology. 1981; 80: 307-312.
52. Weedon DD, Shorter RG, Ilstrup DM, et al. Crohn's disease and cancer. N Engl J Med. 1973; 289: 1099-1103.
53. Weterman IT, Biemond I, Pena AS,. Mortality and causes of death in Crohn's disease. Review of 50 years' experience in Leiden University Hospital. Gut. 1990; 31: 1387-1390.
54. Ekbom A, Helmick CG, Zack M, et al. Survival and causes of death in patients with inflammatory bowel disease: a population-based study. Gastroenterology. 1992; 103: 954-960.
55. Persson PG, Bernell O, Leijonmarck CE, et al. Survival and cause-specific mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology. 1996; 110: 1339-1345.
56. Jess T, Winther KV, Munkholm P, et al. Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Gastroenterology. 2002; 122: 1808-1814.
57. Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology. 1998; 114: 1161-1168.
58. Palli D, Trallori G, Saieva C, et al. General and cancer specific mortality of a population based cohort of patients with inflammatory bowel disease: the Florence Study. Gut. 1998; 42: 175-179.
59. Farrokhyar F, Swarbrick ET, Grace RH, et al. Low mortality in ulcerative colitis and Crohn's disease in three regional centers in England. Am J Gastroenterol. 2001; 96: 501-507.
60. Probert CS, Jayanthi V, Wicks AC, et al. Mortality from Crohn's disease in Leicestershire, 1972-1989: an epidemiological community based study. Gut. 1992; 33: 1226-1228.
61. Cottone M, Magliocco A, Rosselli M, et al. Mortality in patients with Crohn's disease. Scand J Gastroenterol. 1996; 31: 372-375.
62. Canavan C, Abrams KR, Mayberry JF,. Meta-analysis: mortality in Crohn's disease. Aliment Pharmacol Ther. 2007; 25: 861-870.
63. Canavan C, Abrams KR, Hawthorne B, et al. Long-term prognosis in Crohn's disease: an epidemiological study of patients diagnosed more than 20 years ago in Cardiff. Aliment Pharmacol Ther. 2007; 25: 59-65.
64. Wolters FL, Russel MG, Sijbrandij J, et al. The European Collaborative Study Group On Inflammatory Bowel Disease. Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study. Scand J Gastroenterol Suppl. 2006; 46-54.
65. Jess T, Loftus EV Jr, Harmsen WS, et al. Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940-2004. Gut. 2006; 55: 1248-1254.
66. Hutfless SM, Weng X, Liu L, et al. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. Gastroenterology. 2007; 133: 1779-1786.
67. Card T, Hubbard R, Logan RF,. Mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology. 2003; 125: 1583-1590.
68. Lewis JD, Gelfand JM, Troxel AB, et al. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol. 2008; 103: 1428-1435; quiz 1436.
69. Duricova D, Pedersen N, Elkjaer M, et al. Overall and cause-specific mortality in Crohn's disease: a meta-analysis of population-based studies. Inflamm Bowel Dis. 2010; 16: 347-353.
70. Loftus EV Jr,. Mortality in inflammatory bowel disease: peril and promise. Gastroenterology. 2003; 125: 1881-1883.
71. Popivanova BK, Kitamura K, Wu Y, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest. 2008; 118: 560-570.
72. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006; 4: 621-630.
73. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008; 6: 644-653.